Drugs & Aging

, Volume 27, Issue 8, pp 653–661 | Cite as

Treatment with Fall-Risk-Increasing and Fracture-Preventing Drugs Before and After a Hip Fracture

An Observational Study
  • Christina Sjöberg
  • Lina Bladh
  • Lars Klintberg
  • Dan Mellström
  • Claes Ohlsson
  • Susanna M. Wallerstedt
Original Research Article


Background Hip fracture is a common diagnosis in the older population, with often serious consequences. Drug treatment may be of significance for both falls and fractures.

Objective To investigate drug treatment in older hip fracture patients, focusing on use of fall-risk-increasing and fracture-preventing drugs before and after the fracture.

Methods This was an observational study conducted in Sahlgrenska University Hospital, Gothenburg, Sweden. The participants were 100 consecutive hip fracture patients aged ≤65 years with a median age of 86 (range 66–97) years. Seventy-three patients were female, and 87 patients had at least one strong risk factor for a fracture. Four patients died during the hospital stay, and a further 18 died within 6 months after discharge. Treatment with fall-risk-increasing and fracture-preventing drugs at admission to hospital, at discharge and 6 months after the hip fracture was measured.

Results The numbers of patients treated with fall-risk-increasing drugs were 93 (93%), 96 (100%) and 73 (94%) at admission, discharge and 6-month follow-up, respectively. The median (range) number of such drugs was 3 (0–9), 4(1–10) and 3 (0–10), respectively. A total of 17 (17%), 32 (33%) and 29 (37%) patients were treated with fracture-preventing drugs, predominantly calcium plus vitamin D, at admission, discharge and 6-month follow-up, respectively. Five patients (5%) used bisphosphonates or selective estrogen receptor modulators at admission. No additional patients had these drugs prescribed during the hospital stay. At 6-month follow-up, four more patients were treated with bisphosphonates.

Conclusions Treatment with fall-risk-increasing drugs was extensive among older hip fracture patients both before and after the fracture. The proportion of patients with fracture-preventing drugs was low at admission and increased slightly during the follow-up period. Hence, drug treatment in older hip fracture patients can be improved regarding both fall-risk-increasing drugs and fracture-preventing drugs.


  1. 1.
    Johnell O, Gullberg B, Allander E, et al. The apparent incidence of hip fracture in Europe: a study of national register sources. MEDOS Study Group. Osteoporos Int 1992 Nov; 2(6): 298–302PubMedCrossRefGoogle Scholar
  2. 2.
    Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000; 11(8): 669–74PubMedCrossRefGoogle Scholar
  3. 3.
    Hasserius R, Johnell O, Nilsson BE, et al. Hip fracture patients have more vertebral deformities than subjects in population-based studies. Bone 2003 Feb; 32(2): 180–4PubMedCrossRefGoogle Scholar
  4. 4.
    Colon-Emeric C, Kuchibhatla M, Pieper C, et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int 2003 Nov; 14(11): 879–83PubMedCrossRefGoogle Scholar
  5. 5.
    Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003 May; 32(5): 468–73PubMedCrossRefGoogle Scholar
  6. 6.
    Sernbo I, Johnell O. Consequences of a hip fracture: a prospective study over 1 year. Osteoporos Int 1993 May; 3(3): 148–53PubMedCrossRefGoogle Scholar
  7. 7.
    Meyer HE, Tverdal A, Selmer R. Weight variability, weight change and the incidence of hip fracture: a prospective study of 39,000 middle-aged Norwegians. Osteoporos Int 1998; 8(4): 373–8PubMedCrossRefGoogle Scholar
  8. 8.
    Nguyen T, Sambrook P, Kelly P, et al. Prediction of osteoporotic fractures by postural instability and bone density. BMJ 1993 Oct 30; 307(6912): 1111–5PubMedCrossRefGoogle Scholar
  9. 9.
    Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005 Jun; 16(6): 581–9PubMedCrossRefGoogle Scholar
  10. 10.
    Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002 May 18; 359(9319): 1761–7PubMedCrossRefGoogle Scholar
  11. 11.
    Gillespie LD, Gillespie WJ, Robertson MC, et al. Interventions for preventing falls in elderly people. Cochrane Database Syst Rev 2003; (4): CD000340Google Scholar
  12. 12.
    Speechley M, Tinetti M. Falls and injuries in frail and vigorous community elderly persons. J Am Geriatr Soc 1991 Jan; 39(1): 46–52PubMedGoogle Scholar
  13. 13.
    Kallin K. Falls in older people in geriatric care settings. Umeå: Umeå University, 2004Google Scholar
  14. 14.
    Kallin K, Lundin-Olsson L, Jensen J, et al. Predisposing and precipitating factors for falls among older people in residential care. Public Health 2002 Sep; 116(5): 263–71PubMedGoogle Scholar
  15. 15.
    Tangman S, Eriksson S, Gustafson Y, et al. Precipitating factors for falls among patients with dementia on a psychogeriatric ward. Int Psychogeriatr 2010 Feb; 2: 1–9Google Scholar
  16. 16.
    van der Velde N, Stricker BH, Pols HA, et al. Risk of falls after withdrawal of fall-risk-increasing drugs: a prospective cohort study. Br J Clin Pharmacol 2007 Feb; 63(2): 232–7PubMedCrossRefGoogle Scholar
  17. 17.
    Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999 Jan; 47(1): 30–9PubMedGoogle Scholar
  18. 18.
    Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 1999 Jan; 47(1): 40–50PubMedGoogle Scholar
  19. 19.
    Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002 Jun 1; 359(9321): 1929–36PubMedCrossRefGoogle Scholar
  20. 20.
    Melton 3rd LJ. The prevalence of osteoporosis: gender and racial comparison. Calcif Tissue Int 2001 Oct; 69(4): 179–81PubMedCrossRefGoogle Scholar
  21. 21.
    Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005 Jul; 20(7): 1185–94PubMedCrossRefGoogle Scholar
  22. 22.
    Sowers MR, Clark MK, Jannausch ML, et al. Body size, estrogen use and thiazide diuretic use affect 5-year radial bone loss in postmenopausal women. Osteoporos Int 1993 Dec; 3(6): 314–21PubMedCrossRefGoogle Scholar
  23. 23.
    Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007 Jun 25; 167(12): 1240–5PubMedCrossRefGoogle Scholar
  24. 24.
    Berthold HK, Unverdorben S, Zittermann A, et al. Age-dependent effects of atorvastatin on biochemical bone turnover markers: a randomized controlled trial in post-menopausal women. Osteoporos Int 2004 Jun; 15(6): 459–67PubMedCrossRefGoogle Scholar
  25. 25.
    Panneman MJ, Lips P, Sen SS, et al. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 2004 Feb; 15(2): 120–4PubMedCrossRefGoogle Scholar
  26. 26.
    Kanis JA, on behalf of the World Health Organization Scientific Group (2007). Assessment of osteoporosis at the primary health-care level. Technical report. Sheffield: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, 2007Google Scholar
  27. 27.
    Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008 Sep 16; 149(6): 404–15PubMedGoogle Scholar
  28. 28.
    Albertsson DM, Mellstrom D, Petersson C, et al. Validation of a 4-item score predicting hip fracture and mortality risk among elderly women. Ann Fam Med 2007 Jan-Feb; 5(1): 48–56PubMedCrossRefGoogle Scholar
  29. 29.
    The Swedish Medical Products Agency. Treatment of osteoporosis: treatment guidelines. Information från Läkemedelsverket 2007; 18(4): 19–29Google Scholar
  30. 30.
    Campbell AJ, Robertson MC, Gardner MM, et al. Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized, controlled trial. J Am Geriatr Soc 1999 Jul; 47(7): 850–3PubMedGoogle Scholar
  31. 31.
    Lee JS, Kwok T, Leung PC, et al. Medical illnesses are more important than medications as risk factors of falls in older community dwellers? A cross-sectional study. Age Ageing 2006 May; 35(3): 246–51PubMedCrossRefGoogle Scholar
  32. 32.
    Iyer S, Naganathan V, McLachlan AJ, et al. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging 2008; 25(12): 1021–31PubMedCrossRefGoogle Scholar
  33. 33.
    Myers MG, Weingert ME, Fisher RH, et al. Unnecessary diuretic therapy in the elderly. Age Ageing 1982 Nov; 11(4): 213–21PubMedCrossRefGoogle Scholar
  34. 34.
    Nelson MR, Reid CM, Krum H, et al. Predictors of normotension on withdrawal of antihypertensive drugs in elderly patients: prospective study in second Australian national blood pressure study cohort. BMJ 2002 Oct 12; 325(7368): 815–9PubMedCrossRefGoogle Scholar
  35. 35.
    Curran HV, Collins R, Fletcher S, et al. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med 2003 Oct; 33(7): 1223–37PubMedCrossRefGoogle Scholar
  36. 36.
    Lakatos P. Thyroid hormones: beneficial or deleterious for bone? Calcif Tissue Int 2003 Sep; 73(3): 205–9PubMedCrossRefGoogle Scholar
  37. 37.
    Barrett-Connor E, Weiss TW, McHorney CA, et al. Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 2009 May; 20(5): 715–22PubMedCrossRefGoogle Scholar
  38. 38.
    Kallin K, Gustafson Y, Sandman PO, et al. Drugs and falls in older people in geriatric care settings. Aging Clin Exp Res 2004 Aug; 16(4): 270–6PubMedGoogle Scholar
  39. 39.
    Boonen S, Dejaeger E, Vanderschueren D, et al. Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective. Best Pract Res Clin Endocrinol Metab 2008 Oct; 22(5): 765–85PubMedCrossRefGoogle Scholar
  40. 40.
    Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997 Dec 8–22; 157(22): 2617–24PubMedCrossRefGoogle Scholar
  41. 41.
    Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of anti-resorptive agents in the old and oldest old. J Am Geriatr Soc 2004 Nov; 52(11): 1832–9PubMedCrossRefGoogle Scholar
  42. 42.
    Tosi LL, Lane JM. Osteoporosis prevention and the orthopaedic surgeon: when fracture care is not enough. J Bone Joint Surg Am 1998 Nov; 80(11): 1567–9PubMedGoogle Scholar
  43. 43.
    Rabenda V, Vanoverloop J, Fabri V, et al. Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am 2008 Oct; 90(10): 2142–8PubMedCrossRefGoogle Scholar
  44. 44.
    Juby AG, De Geus-Wenceslau CM. Evaluation of osteoporosis treatment in seniors after hip fracture. Osteoporos Int 2002 Mar; 13(3): 205–10PubMedCrossRefGoogle Scholar
  45. 45.
    Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007 Nov 1; 357(18): 1799–809PubMedCrossRefGoogle Scholar
  46. 46.
    Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25(6): 1105–87PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Christina Sjöberg
    • 1
  • Lina Bladh
    • 2
  • Lars Klintberg
    • 3
  • Dan Mellström
    • 1
  • Claes Ohlsson
    • 2
  • Susanna M. Wallerstedt
    • 2
  1. 1.Department of GeriatricsSahlgrenska University HospitalMölndalSweden
  2. 2.Department of Clinical PharmacologySahlgrenska University HospitalGothenburgSweden
  3. 3.Department of MedicineSahlgrenska University HospitalMölndalSweden

Personalised recommendations